Introduction;
The aim of this study was to investigate the safety and feasibility of the high-frequency oscillatory ventilation (HFOV) technique for the management of respiratory motion in patients with thoracoabdominal malignancies undergoing heavy ion precision therapy.
Methods;
A retrospective analysis of clinical data from 30 patients with thoracoabdominal malignant tumors treated with heavy ion therapy under the control of high-frequency oscillatory ventilation at one Cancer Hospital was conducted from January 2023 to March 2024. Patient's general conditions, respiratory motion, and other clinical parameters were analyzed and compared before, during, and after the treatment to determine the value of utilizing HFOV for managing thoracoabdominal malignancies in patients undergoing heavy ion therapy.
Results;
There was no significant difference in heart rate, blood pressure, blood oxygen saturation, or tcpCO2 before, during, or after treatment (P > 0.05). In addition, HFOV improved the patient's tcpO2 values (P < 0.001). However, the lung respiratory motion under HFOV was 1.33 ± 0.39 mm, which was significantly lower than that in the spontaneous respiration status (19.31 ± 4.22mm, P < 0.001), and "missed targeting" was not observed during radiotherapy. Throughout the treatment process, one case complicated with hypertension and hypercapnia was observed, and two patients experienced nausea and vomiting after extubation. Radiation pneumonia occurred in 1 of 30 patients, and the mean hospital stay was 22.13 ± 10.94 days. The results showed that the objective response rate was 93.1%, the complete response rate was 41.37%, and the partial response rate was 51.72%. No death occurred during the follow-up period.
Conclusion;
HFOV is safety for thoracoabdominal tumor patients to receive high doses of precise heavy ion therapy, thereby enhancing treatment efficacy. Further randomized controlled trial is needed to confirm this discovery.